



Published in final edited form as:

*J Nat Prod.* 2003 June ; 66(6): 823–828. doi:10.1021/np020592u.

## New Manzamine Alkaloids with Activity against Infectious and Tropical Parasitic Diseases from an Indonesian Sponge

Karumanchi V. Rao<sup>§</sup>, Bernard D. Santarsiero<sup>‡</sup>, Andrew D. Mesecar<sup>‡</sup>, Raymond F. Schinazi<sup>†</sup>, Babu L. Tekwani<sup>§</sup>, and Mark T. Hamann<sup>\*:§</sup>

<sup>§</sup>The Department of Pharmacognosy and National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, Mississippi 38677

<sup>‡</sup>The Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, Chicago, Illinois 60607

<sup>†</sup>Department of Pediatrics, Emory University/VA Medical Center, Decatur, Georgia 30033

### Abstract

Eleven manzamine type alkaloids, two  $\beta$ -carbolines, and five nucleosides have been isolated from an Indonesian sponge. Among these are the previously characterized 12,34-oxamanzamine A, 12,34-oxamanzamine E, manzamine A (**1**), 8-hydroxymanzamine A, 6-deoxymanzamine X, manzamine E (**2**), manzamine X, manzamine F (**4**), norharman, thymine, 2',3'-didehydro-2',3'-dideoxyuridine, uracil, thymidine, and 2'-deoxyuridine. The structures for the five new compounds have been assigned as 32,33-dihydro-31-hydroxymanzamine A (**3**), 32,33-dihydro-6-hydroxymanzamine A-35-one (**5**), des-*N*-methylxestomanzamine A (**6**), 32,33-dihydro-6,31-dihydroxymanzamine A (**7**), and 1,2,3,4-tetrahydronorharman-1-one (**8**), on the basis of NMR and X-ray data. The bioactivity and SAR of the manzamines against malaria, TB, and leishmania are also presented. The structural revision of two previously reported pyrazoles as uracil and thymine is also discussed.


Manzamines are unique  $\beta$ -carboline alkaloids isolated from Indo-Pacific sponges and characterized by having an intricate nitrogen-containing polycyclic system. In 1986, Higa and co-workers first reported manzamine A from the Okinawan sponge of the genus *Haliclona*.<sup>1</sup> These compounds exhibit a diverse range of bioactivities including cytotoxicity,<sup>1</sup> insecticidal,<sup>2</sup> and antibacterial<sup>3</sup> as well as the exciting curative activity against malaria in animal models.<sup>4,5</sup> Since the first report of manzamine A, an additional 40 manzamine-type alkaloids have been reported from nine different sponge genera.<sup>6,7</sup> In our continuing search for manzamine-related alkaloids with significant activity against infectious diseases, we have identified several novel manzamine alkaloids from an Indonesian sponge, and herein we describe their structure determination and biological activity.

\*To whom correspondence should be addressed. Tel: (662) 915-5730. Fax: (662) 915-6975. mthamann@olemiss.edu.

**Supporting Information Available:** Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra for all new compounds, HMQC spectra for **3**, **5–7**, HMBC spectra for **5–8**, and X-ray data for **3**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## Results and Discussion

The sponge was collected from Indonesia and successively extracted with hexane and acetone. Further workup on the combined extract led to the isolation of the known manzamines: (+)-12,34-oxamanzamine A,<sup>8</sup> (-)-12,34-oxamanzamine E,<sup>8</sup> (+)-manzamine A (1),<sup>1,9</sup> (+)-8-hydroxymanzamine A,<sup>10,11</sup> (+)-6-deoxymanzamine X,<sup>2</sup> (+)-manzamine E (2),<sup>12</sup> (+)-manzamine X,<sup>9</sup> (+)-manzamine F (4),<sup>12</sup> and norharman,<sup>13</sup> along with the new (+)-32,33-dihydro-31-hydroxymanzamine A (3), (+)-32,33-dihydro-6-hydroxymanzamine A-35-one (5), des-*N*-methylxestomanzamine A (6), (+)-32,33-dihydro-6,31-dihydroxymanzamine A (7), and 1,2,3,4-tetrahydronorharman-1-one (8).



Compound **3** was obtained as colorless crystals from MeOH,  $[\alpha]_D^{25} +34.44$  ( $c$  0.9,  $\text{CHCl}_3$ ). 32,33-Dihydro-31-hydroxymanzamine A (**3**) was positive to Dragendorff's reagent, and its IR spectrum suggested the presence of OH and NH functionalities. Compound **3** showed the molecular ion peak at  $m/z$  567.4052 ( $M + H^+$ ), in HRESIMS, which is compatible with the molecular composition of  $\text{C}_{36}\text{H}_{46}\text{N}_4\text{O}_2$  ( $\pm 3.5$  mmu of calcd). The  $^1\text{H}$  NMR data (Table 1) includes aromatic proton resonances similar to those of manzamine E.<sup>12</sup> Spectral data of how **3** differs from manzamine E (**2**) includes the presence of 13 CH carbons (manzamine E has 12 CH carbons) and the absence of the low-field C-31 carbonyl carbon signal of manzamine E. In place of the carbonyl carbon compound **3** has a signal at 70.9 ppm, which correlates with a multiplet at 4.05 ppm in the HMQC spectrum. The presence of this new OH- functionality is confirmed by a number of long-range  $^1\text{H}$ - $^{13}\text{C}$  correlations  $\text{H}_2$ -29 and  $\text{H}_2$ -33 to C-31, Figure 1). Data from  $^1\text{H}$ - $^1\text{H}$ -COSY, HMQC, and HMBC provided a wealth of additional support to justify the gross structure shown for **3**. The relative configurations at




carboline, which were confirmed by COSY, HMQC, and HMBC analysis. The proton at  $\delta$  11.98 was assigned to the NH group and showed long-range correlations with C-4a, C-4b, C-8a, and C-9a carbons of the  $\beta$ -carboline moiety. Furthermore, the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra showed signals ascribable to one carbonyl carbon ( $\delta$  184.5) and two singlet imidazole protons [ $\delta$  8.02 (1H, s), 8.59 (1H, s)]. From the spectral data it is evident that the  $\beta$ -carboline moiety was attached to the imidazole moiety through the carbonyl carbon. The absence of long-range correlations between the carbonyl carbon and the imidazole protons may be due to the tautomeric nature of imidazole moiety. The spectral data ( $^1\text{H}$  and  $^{13}\text{C}$  NMR) of **6** match well with the data of xestomanzamine A,<sup>9</sup> which differs from **6** only by having an additional methyl group. On the basis of the spectral properties and biogenesis,<sup>9</sup> the structure for **6** was established as des-*N*-methylxestomanzamine A.

Compound **7** was obtained as a pale yellow powder. High-resolution ESIMS established the molecular formula as  $\text{C}_{36}\text{H}_{46}\text{N}_4\text{O}_3$  ( $m/z$  583.3477 [ $\text{M} + \text{H}$ ]<sup>+</sup> ( 0.2 mmu of calcd). The spectral data of **7** were similar to those of **3**, with an additional oxygen functionality. The third oxygen atom is shown to be another hydroxy group on the aromatic ring by the  $^1\text{H}$  NMR spectrum, which exhibits five aromatic proton signals instead of six as in compound **3**. By thorough analysis of 2D NMR data (HMBC, Figure 3), the hydroxyl group was placed at C-6, and the structure for **7** was assigned as 32,33-dihydro-6,31-dihydroxymanzamine A. The absolute configuration at the remaining five chiral centers of **7** also appears to be the same as those of **3** inasmuch as both compounds were isolated from the same sponge, and also are comparable to the NOE data and possessed dextrorotation. The absolute stereochemistry at C-31 was elucidated by applying Mosher's method.<sup>14</sup> The values of  $\delta$  [ $(\delta_S - \delta_R)$ , H<sub>2</sub>-29  $\delta$ -0.10 and -0.08, H<sub>2</sub>-30  $\delta$ -0.58 and -0.56, H<sub>2</sub>-32  $\delta$ +0.59 and +0.52, H<sub>2</sub>-33  $\delta$ +0.29 and +0.25] obtained from the  $^1\text{H}$  NMR spectra of MTPA esters indicated that the absolute configuration at C-31 was *R*.

Compound **8** was obtained as a pale yellow powder and was shown by HRESIMS to have the molecular formula  $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_3$  [ $m/z$  187.0866, ( $\text{M} + \text{H}$ )<sup>+</sup>, 0.5 mmu of calcd]. The IR spectrum indicated the presence of NH and CdO groups, and the  $^1\text{H}$  NMR spectrum exhibited the four aromatic protons at  $\delta$  7.59 (d, 8.3 Hz), 7.43 (d, 8.3 Hz), 7.26 (t, 8.5 Hz), and 7.23 (t, 8.5 Hz) and two vicinal aliphatic protons at  $\delta$  3.64 (t, 14.2) and 3.02 (t, 14.1), which suggested a 3,4-dihydro- $\beta$ -carboline moiety. In the  $^{13}\text{C}$  NMR spectrum, 11 carbon signals including five quaternary carbons, four CH carbons, and two CH<sub>2</sub> carbons were observed. On the basis of 2D NMR spectral data compound **8** was characterized as 1,2,3,4-tetrahydronorharman-1-one. Though this compound is commercially available, this is the first report in which the compound occurred from a natural source.

In the present study, the isolated nucleosides or nucleoside bases were identified on the basis of the spectral data (NMR and MS) as thymine,<sup>15,16</sup> 2',3'-didehydro-2',3'-dideoxyuridine,<sup>17</sup> uracil,<sup>15,16</sup> thymidine,<sup>18</sup> and 2'-deoxyuridine.<sup>18</sup>



Careful examination of spectral data (NMR, MS) of thymine and uracil showed that they are similar to the data reported for **9** and **10**, isolated by Mishra et al.<sup>19</sup> (**9**) from the sponge *Suberites vestigium* and Parameswaran et al.<sup>20</sup> (**9** and **10**) from the sponge *Tedania anhelans*. The value of the vicinal proton coupling constant ( $J = 7.57$  Hz) reported for **10** differs from pyrazoles ( $J = 2.1$  Hz).<sup>21</sup> The IR absorption bands reported for **9** at  $1724$  and  $1674$   $\text{cm}^{-1}$  and of **10** at  $1730$  and  $1673$   $\text{cm}^{-1}$  support that they have two carbonyl functional groups. The IR recorded for pyrazole and 4-pyrazolecarboxylic acid (from Aldrich) did not show two carbonyl carbon bands, and the coupling constants in the  $^1\text{H}$  NMR match with the literature values for pyrazoles.<sup>21</sup> On the basis of the reported data,<sup>19,20</sup> we believe that the structures of compounds **9** and **10** should be revised to the common primary metabolites thymine (**9a**) and uracil (**10a**). Without careful examination of coupling constants and IR data, these primary metabolites could easily be assigned as a pyrazole system.

In summary the compounds **3** and **7** are the first manzamine congeners with a hydroxyl group on the C-28–C-34 chain. Compound **5** is the first manzamine congener with a carbonyl group on C-35.

The enormous potential of the marine environment to provide new structural classes with activity against tuberculosis has been recently reported.<sup>22</sup> The in vitro activity of manzamines against *Mycobacterium tuberculosis* (H37Rv), malaria parasite *Plasmodium falciparum*, and *Leishmania donovani*, the causative agent for visceral leishmaniasis, is reported in Table 2. Most manzamines were active against *M. tuberculosis* with MICs  $< 12.5$   $\mu\text{g}/\text{mL}$ . (+)-8-Hydroxymanzamine A had an MIC of  $0.91$   $\mu\text{g}/\text{mL}$ , indicating improved activity for the (+) over the (–) enantiomer.<sup>8</sup> Although compounds **3** and **5** were inactive against malaria and leishmania, these results provide valuable information on the structural moieties required for activity against malaria and leishmania. This observation further supports our previous report<sup>4</sup> which indicates that reduction of the C32–C33 olefin and oxidation of C-31 also significantly reduces the antimalarial activity for the manzamine alkaloids in vivo. These data combined strongly suggest that the ability of the C-34 allylic carbon to form a stabilized carbocation after oxidation both in cell culture and in animals followed by the inherent nucleophilic attack may play a critical role in the biological activity of the manzamine alkaloids against the malarial parasite. The significant differences in biological activities of manzamine A, manzamine E, and their corresponding 12,34-oxa-

derivatives indicate that the C-12 hydroxy, C-34 methine, or the conformation of the lower aliphatic rings plays a key role in the antimalarial and leishmanicidal activity and provides valuable insight into the structural moieties required for activity against the malaria and leishmania parasites. The significant leishmanicidal activity of ircinol A ( $IC_{50}$  0.9  $\mu\text{g/mL}$  and  $IC_{90}$  1.7  $\mu\text{g/mL}$ ) indicates that the  $\beta$ -carboline moiety is not essential for activity against the leishmania parasite in vitro. The cytotoxicities of 6-deoxymanzamine X and manzamine X against A-548, HT-29, H-116, and MS-1 cell lines with  $IC_{50}$  ( $\mu\text{g/mL}$ ), respectively, are as follows: 1.0, 5.1; 0.5, 0.5; 0.5, 5.1; 1.0, 5.1. The anti-HIV activity of manzamine A, 8-hydroxymanzamine A, and 6-deoxymanzamine X against human peripheral blood mononuclear (PBM) cells was determined, with median effective concentrations ( $EC_{50}$ ) respectively of 0.59, 4.2, and 1.6  $\mu\text{M}$ .

The diversity of manzamines that have been isolated from different species of sponges is unusual and raises the question of the origin of these metabolites. Microbial fauna/flora associated with these sponges may be responsible for the production of manzamines, and the observed chemical variation may be due to differences in the sponge-associated microbes in the host as well as the host's ability to transform these unusual alkaloids into secondary products.

## Experimental Section

### General Experimental Procedures

Optical rotations were measured with a JASCO DIP-310 digital polarimeter. The IR spectra were recorded on an ATI Mattson Genesis Series FTIR spectrophotometer. UV spectra were recorded using a Perkin-Elmer Lambda 3B UV/vis spectrometer. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded in  $\text{CDCl}_3$ , MeOD, and  $\text{DMSO}-d_6$  on NMR spectrometers operating at 400 or 500 MHz for  $^1\text{H}$  and 100 or 125 MHz for  $^{13}\text{C}$  NMR. The HRESIMS spectra were measured using a Bioapex FTESI-MS with electrospray ionization. The X-ray diffraction data were collected on an Enraf-Nonius Kappa CCD area detector equipped with a rotating anode X-ray generator and Mo  $K\alpha$  radiation. The SIR-92 direct methods package<sup>23</sup> was used to locate the non-hydrogen atoms, and the WinGX package<sup>24</sup> was used for completing the structure determination. ORTEP<sup>25</sup> was used to generate Figure 4. Silica gel (200–400 mesh) and alumina (63–200  $\mu\text{m}$ ) were obtained from Natland International Corporation ([www.natland.com](http://www.natland.com)) and Scientific Adsorbents Incorporated ([www.saisorb.com](http://www.saisorb.com)), respectively. TLC analyses were carried out on precoated silica gel G<sub>254</sub> or aluminum oxide ALOX-100 UV<sub>254</sub> 500  $\mu\text{m}$ . HPLC was performed on a Waters 510 model system.

### Animal Material

The sponge was collected from vertical slopes between 33 and 40 m from Knife Cape, Manado Bay, Indonesia, on March 20, 2001, and is massively encrusting and extremely fragile. The details of taxonomy and morphology were described previously.<sup>8</sup>

### Extraction and Isolation

The sponge was stored frozen until extracted. The lyophilized sponge (3.8 kg, dry weight) was crushed, homogenized, and then successively extracted with hexane and acetone at



room temperature. TLC analysis indicated that both extracts contained manzamine A, together with various minor alkaloids as detected by Dragendorff reagent. The combined extract (110 g) was subjected to Si gel vacuum liquid chromatography and eluted in order, with dichloromethane (100%), dichloromethane–acetone (9:1, 3:1, 1:1), acetone (100%), chloroform–methanol (1:1), and methanol (100%). A total of nine major fractions were collected, and TLC was utilized to monitor the elution of metabolites.

Fraction 5 (34 g) was rechromatographed on Si gel and eluted with chloroform–acetone to obtain crude manzamine A (3.8 g), which was further purified over alumina (hexane–acetone, 95:5), HPLC (C-8, 100 mm,  $\lambda$  410 nm, flow 19.8 mL/min), and acetonitrile–water (0.1% TFA), to obtain 8-hydroxymanzamine A (40 mg,  $1.0 \times 10^{-3}\%$  dry wt), manzamine A (**1**, 3.2 g,  $8.4 \times 10^{-3}\%$  dry wt), 12,34-oxamanzamine E (4 mg,  $1.0 \times 10^{-4}\%$  dry wt), and 12,34-oxamanzamine A (2.2 mg,  $5.8 \times 10^{-5}\%$  dry wt).

Purification of fraction 6 (22 g, CC, alumina, with hexane–acetone, HPLC using acetonitrile–water gradient (0.1% TFA with a  $22 \times 250$  mm C8 column, 254 nm) gave 6-deoxymanzamine X (40 mg,  $1.0 \times 10^{-3}\%$  dry wt), manzamine A (**1**, 20 mg), manzamine E (**2**, 4 mg,  $1.0 \times 10^{-4}\%$  dry wt), 32,33-dihydro-31-hydroxymanzamine A (**3**, 4 mg,  $1.0 \times 10^{-4}\%$  dry wt), manzamine X (40 mg,  $1.0 \times 10^{-3}\%$  dry wt), manzamine F (**4**, 20 mg,  $5.3 \times 10^{-4}\%$  dry wt), 32,33-dihydro-6-hydroxymanzamine A-35-one (**5**, 4 mg,  $1.0 \times 10^{-4}\%$  dry wt), thymine (12 mg,  $3.2 \times 10^{-4}\%$  dry wt), and des-*N*-methylxestomanzamine-A (**6**, 4 mg,  $1.0 \times 10^{-4}\%$  dry wt).

Column chromatography of fraction 7 (20 g) over Si gel, by eluting with chloroform–methanol (gradient), gave five fractions. Further workup of fraction 2 (CC over alumina, hexane–acetone, followed by HPLC, gradient elution, acetonitrile–water (0.1% TFA,  $22 \times 250$  mm, C8 column, at 380 nm) gave 32,33-dihydro-6,31-dihydroxymanzamine A (**7**, 4 mg,  $1.0 \times 10^{-4}\%$  dry wt), 1,2,3,4-tetrahydronorharman-1-one (**8**, 5 mg,  $1.3 \times 10^{-4}\%$  dry wt), and norharman (5 mg,  $1.3 \times 10^{-4}\%$  dry wt). Purification of fraction 3 gave 10 mg of 2',3'-didehydro-2',3'-dideoxyuridine ( $2.6 \times 10^{-4}\%$  dry wt), fraction 4 on further workup gave 20 mg of uracil ( $5.3 \times 10^{-4}\%$  dry wt) and deoxythymidine (25 mg,  $6.6 \times 10^{-4}\%$  dry wt), and the fifth subfraction gave 2'-deoxyuridine (12 mg,  $3.2 \times 10^{-4}\%$  dry wt).

**32,33-Dihydro-31-hydroxymanzamine A (3):** colorless crystals;  $[\alpha]_D^{25} +34.44$  ( $c$  0.9,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  215, 248, 281, 291, 352, 359 nm; IR ( $\text{CHCl}_3$ )  $\nu_{\text{max}}$  3280, 2954, 2927, 1560, 1493, 1453, 1370, 1276, 1150, 748, 665  $\text{cm}^{-1}$ ; NMR data, see Table 1; HRESIMS  $m/z$  567.4052 (calcd for  $\text{C}_{36}\text{H}_{46}\text{N}_4\text{O}_2$ ,  $[\text{M} + \text{H}]^+$ , 567.4087).

### X-ray Crystallographic Analysis of 3

A suitable needle,  $0.06 \times 0.09 \times 0.45$  mm, of **3** was obtained by slow crystallization from MeOH at room temperature for one week. Crystal data:  $\text{C}_{36}\text{H}_{46}\text{N}_4\text{O}_2 \cdot \text{CH}_3\text{OH}$ , orthorhombic, space group  $P2_12_12_1$ ,  $Z = 8$ , unit cell parameters  $a = 10.2728(1)$  Å,  $b = 15.6215(2)$  Å,  $c = 39.9081(6)$  Å,  $V = 6404.3(1)$  Å<sup>3</sup>,  $T = 150(1)$  K,  $F(000) = 2520$ ,  $\lambda = 0.71073$  Å,  $\mu(\text{Mo K}\alpha) 0.076$  mm<sup>-1</sup>. There are two independent molecules (atoms numbered 1–40 and 51–90) in the asymmetric unit and a molecule of methanol. Final refinement with 8250 reflections ( $\theta_{\text{max}} = 22.5^\circ$ ) led to  $R(F)$ ,  $R(F > 2\sigma)$ , and GOF of 0.0577, 0.0400, and

1.023. Crystallographic data, excluding structure factors, have been deposited with the Cambridge Crystallographic Data Centre with deposition number CCDC 192398. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK [fax: +44(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].

**32,33-Dihydro-6-hydroxymanzamine A-35-one (5):** pale yellow powder; mp >200 °C (dec);  $[\alpha]_D^{25} +10.0$  (*c* 1.0, MeOH); UV (MeOH)  $\lambda_{\max}$  219, 248, 268, 356, 395; IR (CHCl<sub>3</sub>)  $\nu_{\max}$  3324, 2935, 1661, 1559, 1461, 1197, 664 cm<sup>-1</sup>; NMR data, see Table 1; HRESIMS *m/z* 581.3467 (calcd for C<sub>36</sub>H<sub>44</sub>N<sub>4</sub>O<sub>3</sub>, [M + H]<sup>+</sup>, 581.3492).

**Des-*N*-methylxestomanzamine A (6):** yellow powder; mp 192 °C (dec); UV (MeOH)  $\lambda_{\max}$  218, 258, 298, 356, 395; IR (KBr)  $\nu_{\max}$  3425, 3075, 1620, 1210, 1208, 1130 cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  11.98 (1H, s, NH-9), 8.59 (1H, s, H-15), 8.57 (1H, d, *J* = 5.1 Hz, H-3), 8.45 (1H, d, *J* = 8.2 Hz, H-5), 8.31 (1H, d, *J* = 5.1 Hz, H-4), 8.02 (1H, s, H-13), 7.82 (1H, d, *J* = 7.9 Hz, H-8), 7.59 (1H, t, *J* = 7.9 Hz, H-7), 7.30 (1H, t, *J* = 7.9 Hz, H-6); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>)  $\delta$  184.5 (C-10), 142.6 (C-9a), 140.3 (C-15), 140.0 (C-13), 138.3 (C-3), 136.6 (C-1), 136.1 (C-8a), 131.9 (C-4b), 129.9 (C-11), 129.8 (C-7), 122.7 (C-5), 121.1 (C-6), 120.9 (C-4a), 119.8 (C-4), 113.9 (C-8); HRESIMS *m/z* 263.0915 (calcd for C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O, [M + H]<sup>+</sup>, 263.0933).

**32,33-Dihydro-6,31-dihydroxymanzamine A (7):** pale yellow powder;  $[\alpha]_D^{25} +25.9$  (*c* 0.5, MeOH); UV (MeOH)  $\lambda_{\max}$  218, 240, 280, 291, 356, 359 nm; IR (CHCl<sub>3</sub>)  $\nu_{\max}$  3324, 2928, 1649, 1559, 1461, 1194, 675 cm<sup>-1</sup>; NMR data, see Table 1; HRESIMS *m/z* 583.3641 (calcd for C<sub>36</sub>H<sub>46</sub>N<sub>4</sub>O<sub>3</sub>, [M + H]<sup>+</sup>, 583.3643).

#### (*R*)- and (*S*)-MTPA Esters of 32,33-Dihydro-6,31-dihydroxymanzamine A (7)

Compound **7** (0.5 mg) was dissolved in 500  $\mu$ L of pyridine and treated with 5  $\mu$ L of (*R*)-(-)-MTPA chloride at room temperature for 24 h. After addition of MeOH (800  $\mu$ L), the solvent was removed in vacuo, and the residue was purified on SiO<sub>2</sub> TLC (hexane–acetone, 1:1) to afford the (*S*)-MTPA ester (0.1 mg) of **7a**. The (*R*)-MTPA ester (**7b**) of **7** was prepared with (*S*)-(-)-MTPA chloride according to the same procedure as described above.

**(*S*)-MTPA ester of 7:** <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  8.36 (1H, d, *J* = 5.2 Hz, H-3), 8.08 (1H, d, *J* = 5.2 Hz, H-4), 7.84 (1H, d, *J* = 8.8 Hz, H-8), 7.25–7.54 (7H, m, Ph and H-5 and H-7), 6.42 (1H, s, H-11), 5.59 (1H, m, H-15), 5.53 (1H, m, H-16), 4.23 (1H, m, H-31), 2.81 (1H, m, H-30), 2.59 (1H, m, H-30), 2.36 (1H, m, H-32), 1.99 (1H, m, H-32), 1.81 (1H, m, H-33), 1.75 (1H, m, H-33), 1.72 (1H, m, H-29), 1.63 (1H, m, H-29); HRESIMS *m/z* 799.4894 (calcd for C<sub>46</sub>H<sub>53</sub>F<sub>3</sub>N<sub>4</sub>O<sub>5</sub>, [M + H]<sup>+</sup>, 799.4046).

**(*R*)-MTPA ester of 7:** <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  8.35 (1H, d, *J* = 5.3 Hz, H-3), 8.09 (1H, d, *J* = 5.3 Hz, H-4), 7.85 (1H, d, *J* = 2.2 Hz, H-8), 7.25–7.54 (7H, m, Ph and H-7 and H-5), 6.59 (1H, s, H-11), 5.57 (2H, br m, H-15 and H-16), 4.21 (1H, m, H-31), 3.37 (1H, m, H-30), 3.17 (1H, m, H-30), 1.84 (1H, m, H-32), 1.80 (1H, m, H-29), 1.73 (1H, m, H-29), 1.52 (1H, m, H-33), 1.50 (1H, m, H-33), 1.40 (1H, m, H-32); HRESIMS *m/z* 799.4864 [M + H]<sup>+</sup> (calcd for C<sub>46</sub>H<sub>53</sub>F<sub>3</sub>N<sub>4</sub>O<sub>5</sub>, [M + H]<sup>+</sup>, 799.4046).



**1,2,3,4-Tetrahydronorharman-1-one (8):** pale yellow powder; UV (MeOH)  $\lambda_{\max}$  210, 240, 325; IR (CHCl<sub>3</sub>)  $\nu_{\max}$  3424, 2920, 1629, 1085 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  7.59 (1H, d,  $J$  = 8.3 Hz, H-5), 7.43 (1H, d,  $J$  = 8.3 Hz, H-8), 7.26 (1H, t,  $J$  = 8.5 Hz, H-7), 7.23 (1H, t,  $J$  = 8.5 Hz, H-6), 3.64 (1H, t,  $J$  = 14.2 Hz, H-3) 3.02 (1H, t,  $J$  = 14.1 Hz, H-4); <sup>13</sup>C NMR (CD<sub>3</sub>OD)  $\delta$  164.5 (C-1), 138.2 (C-8a), 125.8 (C-9a), 125.0 (C-4b), 124.9 (C-7), 120.2 (C-6), 120.0 (C-4a), 112.4 (C-8), 111.9 (C-5), 41.8 (C-3), 20.6 (C-3); HRESIMS  $m/z$  187.0866 (calcd for C<sub>11</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>, [M + H]<sup>+</sup>, 187.0871).

### In Vitro Antileishmanial Assay

Compounds were screened for antileishmanial activity in vitro on *Leishmania donovani* promastigotes. A transgenic cell line of *L. donovani* promastigotes showing stable expression of luciferase was used as the test organism. Pentamidine and amphotericin B were tested as standard antileishmanials. Antimalarial,<sup>26</sup> antituberculosis,<sup>22</sup> and HIV<sup>27</sup> assays were performed using the referenced procedures.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


### Acknowledgments

We are indebted to Subagus Wahyuono and Achmad Mursyidi from Gadjah Mada University, Indonesia, for assistance with sample collection, John Trott and Sharon Sanders for in vitro malaria assays, and Phillip E. Fanwick, Department of Chemistry, Purdue University, for the X-ray diffraction data. We gratefully acknowledge Sharon C. Sanders and Belynda G. Smiley, the National Center for Natural Products Research, for bioassays. This work was supported by NIH (RO1AI36596, KO2AI01502), UNDP/World Bank/WHO special program for Research and Training in Tropical Diseases (TDR# 990119). R.F.S. is supported by the Emory University Center for AIDS Research and Department of Veterans Affairs.


### References and Notes

1. Sakai R, Higa T, Jefford CW, Bernardinelli G. *J Am Chem Soc.* 1986; 108:6404–6405.
2. Edrada RA, Proksch P, Wray V, Witte L, Muller WEG, Van Soest RWM. *J Nat Prod.* 1996; 59:1056–1060. [PubMed: 8946747]
3. Nakamura H, Deng S, Kobayashi J, Ohizumi Y, Tomotake Y, Matsuzaki T. *Tetrahedron Lett.* 1987; 28:621–624.
4. Ang KKH, Holmes MJ, Higa T, Hamann MT, Kara UAK. *Antimicrob Agents Chemother.* 2000; 44:1645–1649. [PubMed: 10817722]
5. El Sayed KA, Kelly M, Kara UAK, Ang KKH, Katsuyama I, Dunbar DC, Khan AA, Hamann MT. *J Am Chem Soc.* 2001; 123:1804–1808. [PubMed: 11456797]
6. Tsuda M, Kobayashi J. *Heterocycles.* 1997; 46:765–794.
7. Magnier E, Langlois Y. *Tetrahedron.* 1998; 54:6201–6258.
8. (a) Yousaf M, El Sayed KA, Rao KV, Lim CW, Hu J, Kelly M, Franzblau SG, Zhang F, Peraud O, Hill RT, Hamann MT. *Tetrahedron.* 2002; 58:7397–7402. (b) Hu, JF.; Hamann, MT.; Hill, R.; Kelly, M. *The Manzamine Alkaloids.* In: Cordell, GA., editor. *The Alkaloids: Biology and Chemistry.* Elsevier; U.K: 2003. in press
9. Kobayashi M, Yin-Ju C, Aoki S, In Y, Ishida T, Kitagawa I. *Tetrahedron.* 1995; 51:3727–3736.
10. Ichiba T, Corgiat JM, Scheuer PJ, Borges MK. *J Nat Prod.* 1994; 57:168–170. [PubMed: 8158160]
11. Kasanah N, Rao KV, Yousaf M, Wedge DE, Hamann MT. *Tetrahedron Lett.* 2003; 44:1291–1293.
12. Ichiba T, Sakai R, Kohmoto S, Saucy G. *Tetrahedron Lett.* 1988; 29:3083–3086.
13. Inoue S, Okada K, Tanino H, Kakoi H, Goto T. *Chem Lett.* 1980:297–298.


14. Ohtani I, Kusumi T, Kashman Y, Kakisawa H. *J Am Chem Soc.* 1991; 113:4092–4096.
15. Jones AJ, Grant DM, Winkley MW, Robins RK. *J Am Chem Soc.* 1970; 92:4079–4087. [PubMed: 5419046]
16. Clerc, P.; Simon, S. *Tables of Spectral Data for Structure Determination of Organic Compounds.* 2nd. Springer-Verlag; 1989. p. C-211
17. Kondo K, Shigemori H, Ishibashi M, Kobayashi J. *Tetrahedron.* 1992; 48:7145–7148.
18. Chang C, Gomes JD, Byrn SR. *J Org Chem.* 1983; 48:5151–5160.
19. Mishra PD, Wahidullah S, Kamat SY. *Indian J Chem Sect B.* 1998; 37B:199–200.
20. Parameswaran PS, Naik CG, Hegde VR. *J Nat Prod.* 1997; 60:802–803.
21. Pretsch, E.; Buhlmann, P.; Affolter, C. *Structure Determination of Organic Compounds, Tables of Spectral Data.* 3rd. Springer-Verlag; 2000. p. 186
22. El Sayed KA, Bartyzel P, Shen X, Perry TL, Zjawiony JK, Hamann MT. *Tetrahedron.* 2000; 56:949–953.
23. Altomare A, Cascarano G, Giacovazzo C, Guagliardi A. *J Appl Crystallogr.* 1993; 26:343–350.
24. Farrugia LJJ. *Appl Crystallogr.* 1999; 32:837–838.
25. Johnson, CK. ORNL-3794. Oak Ridge National Laboratory; Oak Ridge, TN: 1965.
26. El Sayed KA, Dunbar DC, Goins DK, Cordova CR, Perry TL, Wesson KJ, Sanders SC, Janus SA, Hamann MT. *J Nat Toxins.* 1996; 5:261–285.
27. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, Clair M St, Wilson J, Furman PA, Painter G, Choi WB, Liotta DC. *Antimicrob Agents Chemother.* 1992; 36:2423–2431. [PubMed: 1283296]




**Figure 1.**  
Selected HMBC correlations of 3.



**Figure 2.**  
Selected HMBC correlations of 5.



**Figure 3.**  
Selected HMBC correlations of 7.



**Figure 4.** ORTEP24 drawing of one independent molecule in compound **3**. For simplicity, the numbering scheme used for the X-ray structure depicts connectivity and does not follow the standard IUPAC convention.



Table 1

<sup>1</sup>H and <sup>13</sup>C NMR Data for Compounds **3**, **4**, **5**, and **7** (MeOD)<sup>a</sup>

C no.	<b>32,33-dihydro-31-hydroxymanzamine A (3)</b>		<b>manzamine F (4)</b>		<b>32,33-dihydro-6-hydroxymanzamine A-35-one (5)<sup>b</sup></b>		<b>32,33-dihydro-6,31-dihydroxymanzamine A (7)</b>	
	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H
1	143.1, s		142.3, s		139.4, s		143.5, s	
3	137.7, d	8.30 d, 5.2	137.4, d	8.35 d, 5.3	136.9, d	8.44 d, 5.3	136.7, d	8.22 d, 5.3
4	113.7, d	7.93 d, 5.2	113.8, d	7.82 d, 5.3	114.2, d	8.35 d, 5.3	113.6, d	7.84 d, 5.3
4a	130.3, s		130.1, s		134.8, s		129.9, s	
4b	121.6, s		122.7, s		123.5, s		122.2, s	
5	121.3, d	8.14 d, 8.14	111.3, d	7.61 d, 7.9	105.6, d	7.63 d, 2.3	105.3, d	7.49 d, 2.3
6	119.9, d	7.24 t, 8.0	120.8, d	7.04 t, 8.1	153.2, s		151.4, s	
7	128.5, d	7.53 t, 8.0	113.2, d	7.14 d, 8.0	123.1, d	7.33 dd, 2.3, 8.8	118.5, d	7.09 dd, 2.3, 8.8
8	112.3, d	7.66 d, 8.5	143.5, s		114.1, d	7.68 d, 8.8	113.0, d	7.52 d, 8.8
8a	141.1, s		129.2, s		139.4, s		134.7, s	
9a	133.8, s		133.4, s		136.9, s		136.1, s	
10	141.7, s		141.2, s		143.7, s		139.5, s	
11	137.2, d	6.44 s	137.4, d	6.51 s	143.7, d	6.65 s	136.9, d	6.29 s
12	68.6, s		69.1, s		72.5, s		69.9, s	
13	40.5, t	1.83 m, 1.88 m	40.1, t	1.86 m, 2.02 m	41.2, t	1.85 m, 1.99 m	41.0, t	1.81 m, 1.89 m
14	21.7, t	2.15 m, 2.18 m	21.5, t	2.12 m, 2.21 m	21.6, t	2.11 m, 2.20 m	21.9, t	2.11 m, 2.20 m
15	127.8, d	5.63 q, 12.08	127.9, d	5.64 m	134.8, d	5.62 q, 9.8	128.7, d	5.65 dt, 4.7, 11.38
16	132.7, d	5.52 dt, 4.4, 10.8	130.3, d	5.54 m	127.5, d	5.66 q, 10.1	132.0, d	5.52 q, 9.09
17	25.7, t	1.64 m, 2.49 m	25.2, t	1.63 m, 2.49 m	23.6, t	1.65 m, 2.51 m	26.3, t	1.66 m, 2.48 m
18	26.9, t	1.35 m, 1.42 m	26.8, t	1.32 m, 1.39 m	26.1, t	1.32 m, 1.40 m	27.1, t	1.35 m, 1.41 m
19	25.0, t	1.36 m, 1.69 m	24.8, t	1.40 m, 1.72 m	22.8, t	1.42 m, 1.73 m	22.8, t	1.34 m, 1.71 m
20	52.8, t	2.39 m, 2.60 m	53.1, t	2.37 m, 2.59 m	53.2, t	2.36 m, 2.59 m	53.5, t	2.37 m, 2.62 m
22	49.8, t	1.82 m, 2.70 m	49.6, t	1.90 m, 2.80 m	49.7, t	1.93 m, 2.81 m	50.2, t	1.83 m, 2.71 m
23	33.4, t	1.48 m, 1.95 m	33.6, t	1.56 m, 2.25 m	31.5, t	1.55 m, 2.75 m	32.5, t	1.46 m, 1.85 m
24	42.4, d	3.15 dt, 6.4, 9.3	42.1, d	3.19 m	39.5, d	3.05 dd, 7.1, 10.8	40.1, d	3.15 dd, 7.3, 11.2
25	45.9, s		46.5, s		42.7, s		45.5, s	
26	81.9, d	3.79 s	81.6, d	3.69 s	79.7, d	5.01 s	75.6, d	3.64 s

C no.	32,33-dihydro-31-hydroxymanzamine A (3)		manzamine F (4)		32,33-dihydro-6-hydroxymanzamine A-35-one (5) <sup>b</sup>		32,33-dihydro-6,31-dihydroxymanzamine A (7)	
	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C
28	53.5, t	2.66 m, 3.56 m	53.3, t	2.73 m, 3.39 m	53.2, t	2.69 m, 3.38 m	53.5, t	2.66 m, 3.56 m
29	31.7, t	1.83 m, 1.90 m	32.8, t	1.92 m, 2.02 m	38.1, t	1.83 m, 2.10 m	32.4, t	1.83 m, 1.90 m
30	48.2, t	2.65 m, 2.98 m	45.4, t	2.29 m, 2.55 m	41.2, t	2.45 m, 2.87 m	48.2, t	2.65 m, 2.98 m
31	70.9, d	4.05 m	216.6, s		25.8, t	2.05 m	79.9, d	4.05 m
32	36.8, t	1.80 m, 2.21 m	38.9, t	2.34 m, 2.61 m	23.6, t	1.98 m, 2.31 m	37.2, t	1.80 m, 2.21 m
33	25.0, t	1.60 m, 1.79 m	24.9, t	1.69 m, 2.08 m	31.5, t	1.70 m, 2.10 m	26.3, t	1.60 m, 1.79 m
34	63.8, d	3.05 m	63.6, d	3.01 m	66.9, d	4.13 m	65.4, d	3.2 m
35	46.2, t	1.35 m, 1.42 m	46.4, t	1.52 m, 1.61 m	197.2, s		47.3, t	1.34 m, 1.42 m
36	68.9, t	2.30 m, 2.65 m	68.9, t	2.29 m, 2.48 m	63.5, t	2.33 m, 2.55 m	66.9, t	2.31 m, 2.65 m

<sup>a</sup> 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C NMR carbon multiplicities were determined by DEPT experiments. s = quaternary, d = methine, t = methylene carbons. Coupling constants (*J*) are in Hz.

<sup>b</sup> NMR obtained at 300 MHz.

Table 2

Bioactivity Data for Manzamines<sup>a</sup>

compound	activity in vitro								
	<i>M. tuberculosis</i> (H37Rv)		<i>P. falciparum</i> (D6 clone)		<i>P. falciparum</i> (chlorine-resistant W2 clone)		<i>L. donovani</i>		cytotoxicity (Vero) ng/mL
	MIC µg/mL	IC 50 ng/mL	IC 50 ng/mL	IC 50 ng/mL	IC 50 µg/mL	IC 90 µg/mL	IC 90 µg/mL		
12,34-oxamanzamine A	NT	4760	NA	NA	14	40	40	NC	
<i>ent</i> -12,34-oxamanamine E	128	NA	NA	NA	NA	NA	NA	NC	
manzamine A (1)	1.53	4.5	8.0	8.0	0.9	1.8	1.8	1200	
(+)-8-hydroxymanzamine A	0.91	6.0	8.0	8.0	6.2	11	11	1100	
6-deoxymanzamine X	1.77	1300	1400	1400	3.2	7.5	7.5	4760	
manzamine E (2)	3.76	3400	4760	4760	3.8	6.8	6.8	NC	
manzamine X	NT	950	2000	2000	5.7	11	11	NC	
manzamine F (4)	2.56	780	1700	1700	4.2	7.0	7.0	NC	
32,33-dihydro-31-hydroxymanzamine A (3)	NT	NA	NA	NA	NA	NA	NA	NC	
32,33-dihydro-6-hydroxymanzamine A-35-one (5)	NT	NA	NA	NA	NA	NA	NA	NC	
des- <i>N</i> -methylkestomanzamine A (6)	NT	NA	NA	NA	35	>50	>50	NC	
1,2,3,4-tetrahydronorharman-1-one (8)	NT	NA	NA	NA	NA	NA	NA	NC	
norharman	NT	NA	NA	NA	NA	NA	NA	NC	
rifampin	0.5	NT	NT	NT	NT	NT	NT	NT	
chloroquine	NT	15.5	170	170	NT	NT	NT	NT	
artemisinin	NT	10	6.3	6.3	NT	NT	NT	NT	
pentamidine	NT	NT	NT	NT	2.1	10	10	NT	
amphotericin B	NT	NT	NT	NT	0.06	0.15	0.15	NT	

<sup>a</sup>NA = not active; NT = not tested; NC = no cytotoxicity (concentration: 4760 ng/mL).